
Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.
FDA-approved colorectal cancer blood tests—Shield, Epi proColon, SimpleScreen—expand blood-based screening, but positives still need colonoscopy.
Colonoscopy remains the gold standard for colorectal cancer screening—but it is also underused. Prep burden, procedure anxiety, access barriers, and cost all contribute to a persistent screening gap. Blood-based tests offer a lower-barrier alternative, and the landscape has changed meaningfully in the past 2 years. Here is what pharmacists need to know.






